| Literature DB >> 31883458 |
Yanying An1, Yuqi Ni1, Zhihao Xu2, Shuizhen Shi1, Jiashu He1, Yu Liu1, Ke-Yu Deng1, Mingui Fu3, Meixiu Jiang4, Hong-Bo Xin1.
Abstract
Activated macrophages play an important role in many inflammatory diseases including septic shock and atherosclerosis. TRIM59 has been showed to participate in many pathological processes, such as inflammation, cytotoxicity and tumorigenesis. However, the molecular mechanisms controlling its expression in activated macrophages are not fully understood. Here we report that TRIM59 expression is regulated by Sp1 and Nrf1 in LPS-activated macrophages. TRIM59 is highly expressed in macrophages, and markedly decreased by LPS stimuli in vivo and in vitro. TRIM59 promoter activity is also significantly suppressed by LPS and further analysis demonstrated that Sp1 and Nrf1 directly bound to the proximal promoter of TRIM59 gene. LPS treatment significantly decreased Sp1 expression, nuclear translocation and reduced its binding to the promoter, whereas increased Nrf1 expression, nuclear translocation and enhanced its binding to the promoter. Moreover, LPS-decreased TRIM59 expression was reversed by JNK inhibitor. Finally, TRIM59 level is significantly decreased during atherosclerosis progression. Taken together, our results demonstrated that TRIM59 expression was precisely regulated by Sp1 and Nrf1 in LPS-activated macrophages, which may be dependent on the activation of JNK signaling pathway and TRIM59 may be a potential therapeutic target for inflammatory diseases such as atherosclerosis.Entities:
Keywords: Atherosclerosis; Macrophage; Nrf1; Sp1; TRIM59
Mesh:
Substances:
Year: 2019 PMID: 31883458 PMCID: PMC7773022 DOI: 10.1016/j.cellsig.2019.109522
Source DB: PubMed Journal: Cell Signal ISSN: 0898-6568 Impact factor: 4.315